Jan. 12, 2021 Price forecast | 2 weeks: -3.86% | 1 month: -5.87% | 3 months: -3.83%


CABA stock forecast

Our latest prediction for Cabaletta Bio Inc's stock price was made on the Jan. 12, 2021 when the stock price was at 14.53$.

In the short term (2weeks), CABA's stock price should underperform the market by -3.86%. During that period the price should oscillate between -12.53% and +12.68%.

In the medium term (3months), CABA's stock price should underperform the market by -3.83%. During that period the price should oscillate between -38.19% and +33.20%.

Create a solid portfolio with CABA

Add CABA to your portfolio and optimize it!


About Cabaletta Bio Inc

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.46$ per share.

The book value per share is 4.88$

Cabaletta Bio Inc website


Three months stock forecastJan. 12, 2021


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -30M - -29M -1.46 - - 24M 4.88 -25M -1M -26M